MedTrace Logo

Liver Transplantation and Reticuloendothelial Clearance Capacity

NCT00929032 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2010-10-20

No results posted yet for this study

Summary

Study summary: "Liver transplantation and the reticuloendothelial clearance capacity."

The purpose of this study is to evaluate the effect of liver transplantation on the immune system.

This study will involve the taking of a number of observations but does not involve any treatment, which differs from normal care. Indications for transplantation are solely based on the best clinical practice, which is usually performed at the department.

The study measures liver function based on the clearance of different "marker" substances by the liver. These substances are given intravenously and their clearance will be measured from bloodstream.

All substances used in this study are registered in the United Kingdom for clinical applications and already used in clinical practice over years. They are safe and without any risk to harm individuals under study. Furthermore no side effects or any symptoms caused by the administration of these substances are expected.

Measurements of liver function are undertaken before transplantation, 1 and 7 days following the transplant. There is no restriction from any of the patient's prescribed medication. All blood samples will be removed from the cannula (drip) and will not require repeated injections. It is hoped that this research will lead to a greater understanding of the effects of liver transplantation on the immune system.

Conditions

  • Hepatic Insufficiency
  • Liver Insufficiency

Interventions

RADIATION

Nanocoll®

To determine reticuloendothelial system (RES) phagocytosis activity and liver phagocytic function respectively we will measure plasma clearance of 99mTc labelled micro-aggregated human albumin without any imaging studies.

Sponsors & Collaborators

  • NHS Lothian

    collaborator OTHER_GOV

  • European Society of Organ Transplantation

    collaborator UNKNOWN

  • University of Edinburgh

    lead OTHER

Principal Investigators

  • Stephen J Wigmore, Prof, MD · University of Edinburgh

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-07-31
Completion
2010-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00929032 on ClinicalTrials.gov